<DOC>
	<DOCNO>NCT01384513</DOCNO>
	<brief_summary>The purpose research study compare survival rate patient good risk disease undergo hematopoietic stem cell transplant ( HSCT ) survival rate report medical literature similar patient undergo reduced intensity HSCT match related donor .</brief_summary>
	<brief_title>A Two-Step Approach Reduced Intensity Bone Marrow Transplant Patients With Hematological Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare overall survival ( OS ) rate 2 year post treatment use Jefferson 2 step reduce intensity conditioning ( RIC ) approach patient haploidentical family donor hematological malignancy morphological radiographic remission chemosensitive , indolent disease historical OS rate similar population RIC match donor HSCT report literature . SECONDARY OBJECTIVES : I . To compare treatment-related mortality ( TRM ) rate 2 year patient treat study historical TRM rate patient undergo RIC matched-sibling HSCT report literature . II . To compare 2 year relapse rate relapse related mortality patient myeloid disease patient lymphoid disease treat Thomas Jefferson University ( TJU ) RIC 2 step approach . III . To determine incidence severity graft-versus-host disease ( GVHD ) patient undergo treated TJU RIC 2 step approach . IV . To evaluate engraftment rate lymphoid reconstitution patient treat TJU RIC 2 step approach . V. To evaluate incidence TRM 100 day patient treat TJU RIC 2 step approach . OUTLINE : REDUCED INTENSITY CONDITIONING : Patients receive fludarabine phosphate intravenously ( IV ) 60 minute day -11 -8 bulsufan IV 3 hour day -10 -9 . Patients undergo total body irradiation ( TBI ) day -6 . Patients also receive cyclophosphamide IV 2 hour day -3 -2 . TRANSPLANTATION : Patients undergo donor lymphocyte infusion ( DLI ) day -6 cluster differentiation ( CD ) -34+ allogeneic peripheral blood stem cell transplantation ( PBSCT ) day 0 . GVHD PROPHYLAXIS : Beginning day -1 , patient receive tacrolimus IV orally ( PO ) taper begin day 42 . Patients also receive mycophenolate mofetil IV twice daily ( BID ) day -1 28 . After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Leukemia , Neutrophilic , Chronic</mesh_term>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Any patient hematologic oncologic diagnosis allogeneic HSCT think beneficial , frontline therapy already apply . Patients treat protocol without morphological evidence disease ( complete remission `` CR '' ) , patient evidence disease , patient must least good partial response ( PR ) recent therapy disease must chemoresponsive . 2 . Patients treat study : Acute leukemia 1st 2nd CR MDS ( myelodysplastic syndrome ) , specific subtypes RA ( refractory anemia ) RARS ( refractory anemia ring sideroblast ) subtypes . Hodgkin Indolent NonHodgkin 's lymphoma chemosensitive disease Myeloma without morphological evidence disease , deep PR recent therapy Myeloproliferative disorder least PR current therapy Aplastic Anemia A hematological oncological disease ( list ) meet criteria review ( CR good PR ) . 3 . Patients must relate donor HLA mismatch 2 , 3 , 4 antigen HLAA ; B ; C ; DR loci GVHD direction . ( Patients relate donor HLA identical 1antigen mismatch may treat therapeutic approach , outcomes part statistical aim study ( see Summary section ) . 4 . Patients must adequate organ function : LVEF ( Left ventricular end diastolic function ) &gt; 50 % DLCO ( Diffusing Capacity Lung Carbon Monoxide ) ≥50 % predict correct hemoglobin Adequate liver function define serum bilirubin &lt; 1.8 , AST ALT &lt; 2.5X upper limit normal Creatinine Clearance ≥ 60 mL/min 5 . Performance status ≥ 80 % ( TJU Karnofsky ) patient ≥ 60 year old ≥70 % patient &lt; 60 year old . 6 . HCTCI Score ≤ 4 point patient ≥ 60 year old ≤ 5 point patient &lt; 60 year old . 7 . Patients must willing use contraception childbearing potential 8 . Able give inform consent 1 . Performance status &lt; 80 % ( TJU Karnofsky ) patient ≥ 60 year old &lt; 70 % patient &lt; 60 . 2 . Hematopoietic Cell TransplantComorbidity Index ( HCTCI ) Score &gt; 4 point patient ≥ 60 year old &gt; 5 point patient &lt; 60 . 3 . HIV positive 4 . Active involvement central nervous system malignancy 5 . Inability obtain informed consent 6 . Pregnancy 7 . Patients life expectancy &lt; 6 month reason underlie hematologic/oncologic disorder 8 . Patients receive alemtuzumab within 8 week transplant admission , recently receive horse rabbit antithymocyte globulin antithymocyte globulin level &gt; 2 ugm/ml 9 . Patients evidence another malignancy , exclusive skin cancer require local treatment , enrol protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Allogeneic HSCT</keyword>
	<keyword>Hematopoietic stem cell transplantation</keyword>
</DOC>